Clinical Manual of Blood and Bone Marrow Transplantation

 
 
Wiley-Blackwell (Verlag)
  • erschienen am 19. April 2017
  • |
  • 424 Seiten
 
E-Book | ePUB mit Adobe-DRM | Systemvoraussetzungen
978-1-119-09547-7 (ISBN)
 
Providing the practicing and trainee hematologist with a practical and immediately applicable compendium of answers the Clinical Manual of Blood and Bone Marrow Transplantation covers the spectrum of the hematopoietic cell transplant specialty, in particular practical issues in transplant patient care, and the set up and functioning of a transplant program.
* Supplies the practicing and trainee hematologist with a practical and immediately applicable compendium of answers to clinical questions
* Covers the spectrum of the hematopoietic cell transplant specialty, in particular practical issues in transplant patient care, and the set up and functioning of a transplant program
* Contains concise chapters written with a focus on tables, algorithms and figures to aid rapid referral
* Benefits from expert contributions from an international authorship
1. Auflage
  • Englisch
  • New York
  • |
  • Großbritannien
John Wiley & Sons
  • 13,27 MB
978-1-119-09547-7 (9781119095477)
weitere Ausgaben werden ermittelt
Syed A. Abutalib, MD, Assistant Director, Hematology & Bone Marrow Transplantation Program; Director, Hematopoietic Progenitor Cell Collection Facility, Midwestern Regional Medical Center, Cancer Treatment Centers of America, Zion, IL, USA
Parameswaran Hari, MD, MRCP, MS, Armand Quick - William Stapp Professor of Hematology; Interim Division Chief, Division of Hematology and Oncology; Director, Adult Blood and Marrow Transplant Program; Medical College of Wisconsin, Milwaukee,WI, USA
  • Intro
  • Title Page
  • Copyright Page
  • Contents
  • Contributors
  • Preface
  • Chapter 1 Donor and graft selection strategy
  • Introduction
  • What are the donor options?
  • What are the graft sources?
  • Donor options
  • HLA matching for donor selection
  • HLA matching of UCB
  • HLA antibodies
  • How is DSA tested?
  • Graft composition
  • PB graft
  • BM graft
  • Why is BM graft is preferred in children with hematologic malignancies?
  • UCB graft
  • Which graft type should I use?
  • Non-HLA factors
  • What if more than one HLA-matched donor is available?
  • Summary
  • Abbreviations
  • Selected reading
  • Chapter 2 HLA typing and implications
  • Introduction
  • HLA nomenclature and tissue typing techniques
  • Polymorphism
  • Unrelated donor search and tools for donor search and selection
  • HLA typing for donor search
  • The donor search
  • Classical HLA alleles: Impact of mismatching
  • Non-classical HLA alleles and matching techniques: Impact on outcomes
  • Summary
  • Selected reading
  • Chapter 3 Risk-benefit assessment in allogeneic hematopoietic transplant: Factors, scores, and models
  • Introduction
  • What are the factors to consider prior to HCT?
  • Age
  • Performance status
  • Socioeconomic status
  • Race
  • Organ function
  • Models used for risk-benefit measurement
  • Models estimating incidences of NRM
  • Models estimating relapse risk
  • Models estimating all-cause mortality
  • How to evaluate a patient for fitness for HCT
  • Guidelines on pretransplantation data gathering
  • Summary and practice points for eligibility for HCT
  • Acknowledgments
  • Conflict of interest
  • Selected reading
  • Chapter 4 Donor and recipient pre-transplant evaluation
  • Introduction
  • Donor infectious evaluation
  • History
  • Physical examination
  • Laboratory testing
  • Management
  • Special consideration for potentially unsafe products
  • Donor non-infectious evaluation
  • History
  • Physical examination
  • Laboratory testing
  • Instrumental investigations
  • Special consideration for female donors of child-bearing age group
  • Recipient infectious evaluation
  • History
  • Physical examination
  • Laboratory testing
  • Management
  • Recipient non-infectious evaluation
  • Assessment of disease type and status
  • Assessment of functional status and comorbidities
  • Assessment of psychosocial, financial, and caregiver issues
  • Summary
  • Selected reading
  • Chapter 5 Autologous and allogeneic progenitor cell mobilization
  • Introduction
  • Autologous mobilization
  • When to use plerixafor
  • What if CD34+ cell mobilization fails?
  • Some practical aspects of autologous CD34+ cell mobilization
  • Allogeneic CD34+ cell mobilization
  • What is the best CD34+ cell mobilization regimen for allogeneic healthy volunteer donors?
  • What is the optimal PB CD34+ cell dose for allogeneic hematopoietic cell transplantation?
  • High yield points
  • Selected reading
  • Chapter 6 Hematopoietic stem and progenitor cell collection by apheresis: Techniques and tricks
  • Introduction
  • Collection techniques and devices used
  • Technical/clinical aspects of HPC (A) collections
  • Vascular access
  • Large volume leukapheresis (LVL)
  • Anticoagulation during HPC (A) collection
  • Special considerations for pediatric HPC donors/patients
  • Efficiency of CD34+ cell collection
  • Prediction by pre-collection CD34+ count and its impact on HPC (A) collection
  • Adverse effects associated with HPC (A) collections
  • HPC (A) collection quality indicators
  • Summary
  • Conflict of Interest
  • Selected reading
  • Chapter 7 Hematopoietic cell processing: From procurement to infusion
  • Introduction
  • Regulations
  • Processing of autologous products
  • Optimizing cell concentrations during processing
  • Cryopreservation: Storing HPC? products for use at a later date
  • Graft infusion: Wash or not to wash?
  • DMSO associated adverse effects and prevention
  • Freezing process
  • Controlled rate versus uncontrolled rate
  • Vapor phase?LN2 versus liquid phase LN2
  • Processing allogeneic products
  • HPC, apheresis allogeneic products
  • HPC, marrow allogeneic products
  • HPC, cord blood allogeneic products
  • Regulation of handling? UCB
  • Potency of the HPC product
  • Infectious disease testing
  • Cell selection
  • Selected reading
  • Chapter 8 Graft manipulation: T-cell depletion and beyond
  • Introduction
  • Acute and chronic GvHD: Scope of the problem
  • Concepts and methods of TCD
  • Negative selection
  • Positive selection
  • Impact of T-cell depletion on engraftment
  • Impact of TCD on GvHD
  • Impact of TCD on GvHD: Comparisons with conventional allo-HCT
  • Impact of TCD on malignant relapse
  • Impact of TCD on immune recovery
  • Optimal patient selection for TCD allografts
  • Future directions: Other approaches to TCD
  • Summary
  • Selected reading
  • Chapter 9 Graft-versus-host disease prophylaxis
  • Historic perspective
  • Donor selection
  • Pharmacological prophylaxis for GvHD
  • Combinations using calcineurin inhibitors
  • 1-Cyclosporine plus methotrexate
  • 2-Tacrolimus (FK 506) plus methotrexte
  • 3-Calcineurin inhibitors plus mycophenolate mofetil (MMF)
  • Sirolimus (rapamycin)
  • Pharmacologic T-cell depletion
  • 1-Antithymocyte globulin (ATG)
  • 2-Alemtuzumab (campath-1H)
  • Investigational therapies
  • Use of post-transplant cyclophosphamide (ptCy) to prevent GvHD
  • Selected reading
  • Chapter 10 Acute lymphoblastic leukemia
  • Introduction
  • ALL risk stratification - an evolving paradigm
  • Has MRD refined the risk-directed strategy for adult ALL?
  • Philadelphia chromosome-negative (Ph-) ALL
  • Philadelphia chromosome-positive (Ph+) ALL
  • Optimal post-remission therapy for adults with ALL in CR1
  • Data with myeloablative conditioning regimen and HLA-MSD and HLA-matched Urelated Donor
  • Philadelphia chromosome-positive (Ph+) ALL
  • Transplant from an alternative donor using MAC/ regimen in CR1
  • HLA-MUD transplants
  • Cord blood transplants
  • HLA-Haploidentical transplants
  • MAC allo-HCT beyond CR1
  • Emerging role for RIC regimens in ALL
  • Does intensity of conditioning regimen matters in ALL?
  • How to evaluate MRD after allo-HCT and what action to take?
  • Is there evidence to merit chimerism monitoring in ALL?
  • Does DLI post-allo-HCT for ALL work?
  • Post-allo-HCT TKI for Ph+ ALL
  • Relapse post-allo-HCT
  • Selected reading
  • Chapter 11 Acute myeloid leukemia
  • Introduction
  • Current results
  • Transplant versus chemotherapy for post-remission therapy
  • Who should receive allogeneic transplant?
  • Is allogeneic transplant needed?
  • Timing of allogeneic transplant
  • Transplant in relapsed or refractory? AML
  • Measurable residual disease (MRD)
  • Types of grafts
  • Donor selection
  • Conditioning regimens
  • Myeloablative regimens
  • Reduced-intensity conditioning (RIC)
  • Post-transplant strategies to prevent relapse
  • Selected reading
  • Chapter 12 Myelodysplastic syndromes
  • Introduction
  • Disease classification, risk stratification, and allo-HCT
  • Indications for transplantation
  • Transplant assessment
  • Patient characteristics
  • Optimal conditioning regimen: Do we know?
  • Donor-recipient immunity
  • Graft source
  • Graft from peripheral blood or marrow?
  • Beyond HLA-matched grafts: Is it reasonable approach?
  • Role of therapy and disease burden prior to allo-HCT
  • Post-transplant outcomes
  • Treatment and prevention of post-?HCT relapse
  • Limitations and future prospects
  • Selected reading
  • Chapter 13 Chronic myelogenous leukemia
  • The past informs the present: lessons from the BMT era
  • Does disease phase matter?
  • Time before transplant and outcome
  • Does the preparative regimen matter?
  • Does donor type affect outcome?
  • Peripheral blood or bone marrow?
  • Is there an established role for T-cell depletion?
  • Up-front allogeneic HCT for first chronic phase: Why or why not?
  • OK, who should get a transplant?
  • Management of post-transplant relapse
  • Monitoring disease post-transplant: Can relapse be prevented?
  • Is there a role for autologous transplantation?
  • Selected reading
  • Chapter 14 Philadelphia chromosome negative myeloproliferative neoplasms
  • Introduction
  • Prospective and retrospective studies of allo-HCT
  • What is the optimal conditioning regimen for PMF?
  • Role of molecular markers
  • Bone marrow fibrosis regression: Is it possible after allo-HCT?
  • Selecting the optimal donor
  • Disease-specific risk scores and optimal timing of allo-HCT
  • Role of spleen size and splenectomy in anticipation for allo-CT
  • Role of JAK inhibition prior to allo-HCT
  • The problem of graft failure and poor graft function
  • Leukemic transformation
  • Treatment and prevention of relapse after allo-HCT
  • Conflict of Interest Statements
  • Selected reading
  • Chapter 15 Chronic lymphocytic leukemia
  • Introduction
  • Allogeneic transplant in CLL: Is this required in an indolent disease?
  • What are prospectively validated negative predictors for response and survival?
  • "High-risk CLL": What does this imply?
  • What is the evidence for the efficacy of allo-HCT in CLL?
  • What are adverse events and risks associated with allo-HCT in CLL?
  • What determines the success of allo-HCT in CLL?
  • Should MRD kinetics and GvL activity be monitored after allo-HCT?
  • What is the outcome of patients who relapse after allo-HCT?
  • Is there a role for autologous hematopoietic cell transplantation in CLL?
  • Do alternative immunochemotherapy-based treatment options for patients with p53 abnormalities exist?
  • Are novel treatments changing the standard of care in CLL?
  • Are novel agents active in high-risk CLL patients?
  • Are there additional limitations to novel agents?
  • What are the limitations of CAR T-cells?
  • Is allo-HCT still a valid treatment option in the era of novel treatments?
  • Which patients should be offered allo-HCT in the era of novel agents?
  • Conflict of interest
  • Selected reading
  • Chapter 16 Hodgkin Lymphoma
  • Introduction
  • Auto-HCT?for Hodgkin Lymphoma: The HD 01 trial
  • Prognostic factors for long-term outcomes after autologous-?HCT
  • First-line salvage chemotherapy before auto-HCT
  • Salvage therapy and effect on graft mobilization
  • Positive PET-CT and role of second-line salvage for patients eligible for high-dose therapy: The role of brentuximab vedotin
  • Can we improve the results of auto-HCT?
  • Tandem transplant versus consolidation therapy after auto-HCT
  • Hodgkin Lymphoma relapsing after first auto-HCT: Allogeneic HCT or second auto-HCT?
  • Allo-HCT for Hodgkin Lymphoma
  • Allogeneic transplantation in patients failing after an auto-HCT
  • Moving allo-HCT to earlier phase of the disease
  • Do we have any evidence of a GvHL effect?
  • Increasing the pool of donors for HL patients having an allo-HCT: Beyond HLA-MSD and HLA-MUD
  • Cord blood transplants in HL
  • HLA-haploidentical transplants in HL
  • Relapses after allo-HCT
  • Selected reading
  • Chapter 17 Indolent lymphomas
  • Introduction
  • Follicular lymphoma
  • HCT in first remission: Auto-HCT versus allo-HCT
  • HCT for relapsed FL: Auto-HCT versus MA- allo-HCT
  • HCT for relapsed FL: Auto-HCT versus RIC allo-HCT
  • HCT for relapsed FL: Chemoimmunotherapy/allo-HCT versus tandem auto/allo-HCT
  • Post auto-HCT maintenance therapy in FL: Where are we now?
  • Transformed FL: Is there a role for HCT?
  • Mantle cell lymphoma
  • Upfront auto-HCT in MCL: Transplant in first remission
  • Relapsed/refractory MCL: Auto-HCT versus allo-HCT
  • Waldenström macroglobulinemia
  • Marginal zone lymphomas
  • Small lymphocytic lymphomas
  • Auto-HCT and second malignancies
  • Future efforts directed on improving the role of HCT in indolent lymphomas
  • Selected reading
  • Chapter 18 Diffuse large B-cell lymphoma
  • Introduction
  • Risk stratification - The Revised International Prognostic Index: Is it still relevant?
  • What is the consensus for auto-HCT in R/R DLBCL?
  • Should rituximab be part of the first salvage regimen?
  • Does duration of first remission and exposure to rituximab as part of initial therapy influence subsequent outcome?
  • Is there one best salvage regimen for patients with R/R DLBCL?
  • Incorporation of Ofatumumab in R/R DLBCL
  • Does cell of origin of de novo DLBCL and c-MYC gene rearrangement influence the outcomes with auto-HCT?
  • Frontline autologous-HCT: Yes or no?
  • What is the ideal conditioning regimen for auto-HCT?
  • Rituximab as post-transplant maintenance therapy: Yes or no?
  • Post-auto-HCT maintenance therapy: Novel approaches are underway
  • Outcomes of auto-HCT in patients who failed the first salvage regimen
  • Allogeneic-HCT for DLBCL: Eligibility and timing
  • What are the results of allo-HCT in DLBCL?
  • GvL effect: Does it apply in DLBCL?
  • Conditioning regimen for allogeneic HCT: What is the correct intensity?
  • Selected reading
  • Chapter 19 Mantle cell lymphoma
  • Introduction
  • Risk stratification
  • Front line therapy in MCL
  • Younger, fit patients
  • Is the addition of rituximab and/or cytarabine to frontline therapy beneficial?
  • Is intensification of induction therapy beneficial?
  • Elderly or "unfit" patients (unfit to receive auto-HCT)
  • Frail patients
  • Consolidation/maintenance treatment after frontline therapy
  • For transplant eligible patients (young "fit" patients)
  • For transplant-ineligible patients (elderly patients)
  • Is maintenance therapy a suitable alternative for auto-HCT in transplant eligible patients?
  • What is the role of radioimmunotherapy consolidation in MCL?
  • Conditioning regimen for auto-HCT in MCL - Does it matter?
  • Post-auto-HCT maintenance therapy in MCL - are we there yet?
  • Relapsed/refractory MCL - what are the options?
  • Relapsed/refractory patients eligible for transplant
  • Relapsed/refractory patients ineligible for transplant
  • Conundrums in MCL
  • Is a risk-adapted approach feasible?
  • Novel agents - what are the challenges faced?
  • Minimal residual disease analysis - is it ready for prime time?
  • Conclusions
  • Selected reading
  • Chapter 20 T-cell lymphoma
  • Introduction
  • What are the subtypes of PTCL and what are their geographic distributions?
  • What is the standard evaluation for a patient suspected to have PTCL?
  • Is there a standard upfront regimen for T-NHLs (excluding CTCL/MF)?
  • What agents are available for relapsed or refractory disease?
  • Data for HCT (auto and allo) in PTCL
  • Role of frontline auto-HCT
  • Role of frontline allo-HCT
  • Selected reading
  • Chapter 21 Primary CNS lymphoma
  • Introduction
  • Epidemiology, pathology, and clinical presentation
  • Auto-HCT in the setting of recurrent or refractory PCNSL: Does it work?
  • Auto-HCT as front line treatment: Is there a straightforward answer?
  • Comparison between types of consolidation: Non-myeloablative chemotherapy versus auto-HCT
  • Eligibility criteria for auto-HCT
  • Is HIV associated Primary CNS lymphoma a contraindication for auto-HCT?
  • What is the best induction regimen before auto-HCT?
  • Is achievement of complete remission necessary before proceeding to consolidation with auto-HCT?
  • Conditioning regimen: Is there a standard?
  • What is the role of WBRT?
  • What is the role of intrathecal chemotherapy?
  • Conclusion
  • Selected reading
  • Chapter 22 Autologous hematopoietic transplant in multiple myeloma
  • Introduction
  • What is the role of induction therapy prior to auto-HCT?
  • Addition of third agent with a backbone of VD: Is that a standard?
  • Is auto-HCT reasonable after excellent responses from three-drug combination?
  • What is the role of chemotherapy induced mobilization?
  • Choice of conditioning
  • The addition of bortezomib appears to add benefit
  • Consolidation therapy
  • Tandem auto-HCT as consolidation
  • Combination of novel agents in consolidation after auto-HCT
  • Choice of maintenance therapy
  • Age as a factor for auto-HCT: What is the upper limit?
  • Allogeneic HCT
  • Cellular therapy
  • NK-cells
  • CAR T-cells
  • Dendritic cell vaccines
  • Conclusion
  • Selected reading
  • Chapter 23 Allogeneic hematopoietic transplant in multiple myeloma
  • Introduction
  • Allogeneic transplant in MM: How did we get here?
  • What are the randomized data regarding the role of upfront allo-HCT in MM?
  • Why is there discrepancy between randomized study results?
  • Graft-versus-MM effect: Does it exist?
  • Selection of patients for allo-HCT - Defining risk
  • Deciding on allo-HCT for the high-risk MM patient in practice
  • Does allo-HCT benefit high-risk patients or after relapse?
  • Timing of allo-HCT: Upfront or at early relapse or late relapse?
  • Plasma cell leukemia and allo-HCT
  • Planned post-transplant maintenance or cell therapy after allo-HCT
  • Minimal residual disease (MRD) evaluation in allo-HCT
  • Relapse after allo-HCT in MM
  • Emerging immunotherapy approaches
  • Summary
  • Selected reading
  • Chapter 24 Light-chain amyloidosis
  • Introduction
  • History and current data of transplantation for AL amyloidosis
  • Do patients need induction chemotherapy prior to auto-HCT?
  • Mobilization and collection of CD34+ cells
  • Conditioning chemotherapy
  • Supportive care: Important aspects in candidates for auto-HCT
  • Post-transplant consolidation
  • Response to treatment
  • Role of allogeneic transplant in AL amyloidosis
  • Role of solid organ transplant in AL amyloidosis
  • Non-transplant chemotherapy options
  • Current status and future directions
  • Selected reading
  • Chapter 25 Autoimmune disorders
  • Introduction
  • Strategies employing HCT in AID
  • Transplant activity, indications, and outcomes
  • Autologous hematopoietic cell mobilization and collection
  • Conditioning regimens for autologous HCT
  • Early and late complications of HCT and supportive care during HCT
  • Summary key points
  • Selected reading
  • Chapter 26 Testicular cancer
  • Introduction
  • Prognostic factors
  • AHCT for GCT: What are the outcomes and which patient should be considered?
  • So why does widespread use of HDCT/AHCT for relapsed GCTs continue?
  • HDCT/AHCT: How is it done?
  • Efficacy and Toxicity: How can we maximize efficacy while limiting the toxicity?
  • Selected reading
  • Chapter 27 Sickle cell disease
  • Introduction
  • The importance of tracking the natural history of sickle cell disease (SCD)
  • The changing indications for allo-HCT in SCD
  • Traditional indications for allo-HCT
  • Additional indications that signal severity of SCD but can add to allo-HCT toxicities
  • Relative contraindications to allo-HCT in SCD-will increase allo-HCT related morbidity/mortality
  • Donor availability for allo-HCT
  • Transplant trials in SCD - Preparative regimens
  • Outcomes of HCT for SCD
  • Toxicities and supportive care - Not to be forgotten after HCT
  • SCD related risks/precautions
  • Transplant-related risks
  • Long-term follow up
  • Summary
  • Selected reading
  • Chapter 28 Hematopoietic cell transplant in thalassemia
  • Introduction
  • Rationale for allo-HCT
  • Expected results of transplantation for thalassemia
  • Indications for allo-HCT in thalassemia
  • Risk factors for outcomes with allo-HCT in thalassemia
  • Pesaro results (1980s to early 1990s)
  • Lessons from the Pesaro experience
  • Current results with allo-HCT in thalassemia
  • Adult patients (=18?years)
  • HLA-matched sibling cord blood transplant
  • Beyond HLA-MSD and HLA-matched sibling CB units
  • Non-HLA-identical family donor
  • HLA-matched unrelated donor (MUD)
  • Pretransplantation assessment
  • Should a spleenectomy be performed?
  • What about cardiac status?
  • Transplant management
  • Outcome of graft source other than bone marrow in an HLA-MSD setting
  • Myeloablative condition (MAC) regimen is preferred
  • GvHD prophylaxis: Regimen and duration
  • Follow-up evaluation post-transplant
  • Interpretation of chimerism and its implications
  • Follow-up of chimerism
  • Second transplant
  • Other important management aspects after allo-HCT
  • Iron overload: Still an issue
  • Chronic hepatitis and liver fibrosis
  • Endocrine dysfunction
  • Long-term health-related quality of life
  • Selected reading
  • Chapter 29 Fanconi anemia
  • Introduction
  • Historical perspective of allo-HCT in FA
  • Allo-HCT for FA patients: Appropriate candidate and timing
  • What is the consensus on conditioning regimen and GvHD prophylaxis for allo-HCT in patients with FA?
  • Hematologic malignancies in FA patients: Should chemotherapy be performed before allo-HCT?
  • Long-term follow-up after allo-HCT in FA patients: Challenges?
  • High yield points
  • Follow-up before and after allo-HCT
  • Selected reading
  • Chapter 30 Immunodeficiency disorders
  • Introduction
  • Timing - When do the benefits outweigh the risks?
  • What are key differences between allo-HCT for PID and allo-HCT for malignancy?
  • Donor Selection - What to do when there is no HLA-matched sibling
  • Conditioning intensity
  • Chimerism and cure: How much is enough?
  • Infectious issues
  • High yield points
  • Selected reading
  • Chapter 31 Inherited metabolic disorders
  • Introduction
  • Allogeneic-HCT in IEM: What is the rationale and how did we get here?
  • Which diseases to transplant?
  • Are outcomes of HCT in IEM satisfying and how can we further optimize the outcomes?
  • Hurler syndrome, MPS-1H
  • Leukodystrophies
  • When to do allo-HCT?
  • How to transplant a patient with an IEM?
  • Are there alternative treatment options for patients with an IEM?
  • Adjuvant therapies to allo-HCT
  • High yield points
  • Selected reading
  • Chapter 32 Aplastic anemia and paroxysmal nocturnal hemoglobinuria
  • Introduction
  • Diagnostic approach: Differentiating between toxic damage and inherited marrow failure
  • Treatment options for SAA
  • Best treatment option for younger patients: HLA-matched sibling allo-HCT
  • When patients fail or relapse after IST
  • Is it appropriate to use a HLA-mismatched unrelated donor (MMUD)?
  • What about patients who fail multiple attempts at immune suppression and don't have HLA-MUD: Do they have transplantation options?
  • A word about paroxysmal nocturnal hemoglobinuria
  • How should SAA patients be followed after therapy?
  • SAA Patients treated with IST
  • SAA patients treated with allo-HCT
  • High yield points
  • Selected reading
  • Chapter 33 HIV infection and transplantation
  • Introduction
  • Evaluation of a suspected patient with HIV lymphoma
  • Treatment principles
  • AHCT
  • How did we get here?
  • What are the data with AHCT in HIV associated lymphoma?
  • Discrepancy between studies
  • Which patients are suitable candidates for AHCT?
  • Allogeneic transplantation in HIV
  • Allo-HCT in HIV
  • History
  • Data for allo-HCT in HIV infected individuals: Where do we stand?
  • Allo-HCT in hematologic malignancies: Moving forward
  • Allo-HCT for HIV infection
  • Gene therapy for HIV infection
  • Selected reading
  • Chapter 34 Engraftment and graft failure: Assessment and practical considerations
  • Introduction
  • Engraftment assessment
  • Methods for chimerism analysis
  • How to select suitable STR markers for chimerism analysis
  • Which cells are used for chimerism/engraftment analysis?
  • Chimerism and reduced-intensity conditioning
  • Detection of imminent leukemia relapse post-transplant by chimerism analysis
  • Graft failure
  • Primary graft failure
  • Secondary graft failure
  • Major risk factors for graft failure
  • Treatment of graft failure
  • Selected reading
  • Chapter 35 Immune reconstitution and tolerance
  • Introduction
  • When and how are the different immune components reconstituted?
  • Homing and engraftment
  • Innate immunity
  • Adaptive immunity
  • Early post-transplantation period relies on homeostatic peripheral expansion
  • Thymopoiesis recovery is delayed after HCT: Why and how do I monitor its recovery?
  • How does tolerance develop after HCT?
  • What are the different strategies to enhance immune reconstitution following transplantation?
  • Summary
  • Selected reading
  • Chapter 36 Donor lymphocyte infusion
  • What is the rationale for donor lymphocyte infusions (DLIs)?
  • What factors should be considered in deciding to proceed with a DLI?
  • How are donor lymphocytes collected?
  • How is a DLI administered?
  • What is an optimal dose of CD3+ cells?
  • Frequency of DLIs?
  • Should the DLI be preceded by disease specific therapy?
  • Is there a role for recipient lymphodepletion prior to DLI?
  • Should the recipient be on immunosuppression at the time of DLI?
  • How long does it take for a DLI to work?
  • What are the side effects of DLI?
  • How effective is DLI?
  • Limitations of data regarding DLI
  • What are some of the disease specific considerations for DLIs?
  • CML
  • AML
  • ALL
  • Multiple myeloma
  • Low-grade NHL, CLL, and MCL
  • Aggressive NHL
  • Hodgkin's lymphoma
  • Nonmalignant diseases
  • Summary points
  • Selected reading
  • Chapter 37 Diagnosis and treatment of acute graft-versus-host disease
  • Introduction
  • Pathophysiology and risk factors of aGvHD
  • Do we completely understand the pathophysiology of aGvHD?
  • Some important risk factors associated with aGvHD
  • Diagnosis and clinical manifestations of aGvHD
  • How is aGvHD defined?
  • What are the chances of getting aGvHD and what is the usual timing?
  • Clinical manifestations of gastrointestinal GvHD
  • Clinical manifestations of cutaneous GvHD
  • Clinical manifestations of hepatic GvHD
  • What is the differential diagnosis of aGvHD?
  • Is biopsy necessary in diagnosing aGvHD?
  • Is radiographic imaging needed in diagnosing aGvHD?
  • Grading aGvHD - Is one classification better than the other?
  • Treatment of aGvHD
  • Who does not need systemic therapy for aGvHD?
  • How should corticosteroids be given for initial therapy of aGvHD?
  • Should another drug be added to corticosteroids for initial therapy of aGvHD?
  • What should be used when first-line therapy for aGvHD fails?
  • What supportive care measures can be used for aGvHD?
  • What is the prognosis of patients with aGvHD?
  • Summary of diagnosis and treatment of aGvHD
  • Selected reading
  • Chapter 38 Diagnosis and treatment of chronic graft-versus-host disease
  • Introduction
  • Diagnostic criteria
  • Definition and clinical manifestations
  • GvHD global severity score
  • How effective is aGvHD prophylaxis for cGvHD?
  • How about rituximab for prevention of cGvHD?
  • T-cell depletion for cGvHD
  • cGvHD in cord blood transplants and HLA-haploidentical transplants with post cyclophosphamide
  • What is the best initial therapy for cGvHD?
  • Steroids in cGvHD: Dose and schedule?
  • What are the second-line treatment options?
  • Rituximab
  • Extracorporeal photopheresis
  • Imatinib and dasatinib
  • Sirolimus
  • Mycophenolate mofetil (MMF)
  • Bortezomib
  • Is there a role for cellular therapy in prevention or treatment of cGvHD?
  • Treg-cells: Do they really work in cGvHD?
  • Mesenchymal stem cells
  • Supportive care
  • Monitoring for cGvHD
  • Prevention of infections
  • Does treatment of cGvHD increase relapse-related mortality?
  • Selected reading
  • Chapter 39 Prevention and treatment of infection
  • Introduction
  • Prevention of bacterial infections
  • Antibacterial prophylaxis: Challenge in the era of multi-resistance
  • Prevention of bacterial infections after PMN engraftment
  • Prevention of fungal infections
  • How to plan an antifungal prophylaxis strategy
  • Secondary antifungal prophylaxis
  • Prophylaxis of Pneumocystis pneumonia
  • Prevention of viral infections in HCT patients
  • Prophylaxis of herpesvirus diseases
  • Prophylaxis of HBV reactivation
  • Treatment of infections in HCT recipients
  • Neutropenic fever in HCT recipients
  • Fever in non-neutropenic HCT recipients
  • Summary
  • Selected reading
  • Chapter 40 Early non-infectious complications after hematopoietic cell transplantation
  • Introduction
  • How can we grade regimen-related toxicities?
  • Oral mucositis
  • Pathophysiology
  • Risk factors
  • Prophylaxis
  • Management
  • Gastrointestinal and hepatic complications
  • Nausea, vomiting, and anorexia
  • Treatment
  • Esophagitis and gastritis
  • First-line treatments
  • Proton-pump inhibitors (PPIs)
  • H2 antagonists (ranitidine, famotidine, nizatidine, cimetidine)
  • Sucralfate
  • Diarrhea
  • Treatments
  • Sinusoidal obstruction syndrome (SOS)
  • Risk factors
  • Diagnosis
  • Prevention and treatment
  • Pulmonary Complications
  • Diffused alveolar hemorrhage
  • Diagnosis
  • Treatment
  • Idiopathic pneumonia syndrome
  • Diagnosis
  • Treatment
  • Engraftment syndrome
  • Treatment
  • Kidney and bladder complications
  • Acute kidney injury
  • Common etiologies and managements
  • Hemorrhagic cystitis
  • Prevention
  • Treatment
  • Fluid overload
  • Selected reading
  • Chapter 41 Post-transplant lymphoproliferative disorders
  • Introduction
  • EBV biology
  • Pathogenesis
  • Presentation and diagnosis
  • Management of disease
  • Removal/reduction of immune suppression
  • Monoclonal antibody against CD 20 receptor on B-cells
  • EBV-specific T-cell therapy
  • Other therapies
  • Selected reading
  • Chapter 42 Survivorship issues after transplantation
  • Introduction
  • What are the late complications after HCT?
  • Secondary malignancies
  • PTLD
  • Secondary AML/MDS
  • Secondary solid malignancies
  • Which type of secondary solid malignancies occur after HCT?
  • What are the risk factors for secondary solid malignancies?
  • Pre-transplant risk factors
  • Transplant-associated risk factors
  • Post-transplant risk factors
  • Screening for secondary malignancies: What are the recommendations?
  • Late infectious complications
  • Bacterial infections
  • Fungal infections
  • Viral infections
  • What are the vaccination recommendations for HCT recipients?
  • What are the vaccination recommendations for close contacts?
  • New considerations: Pre-transplant vaccines
  • Models for providing long-term care
  • Selected reading
  • Index
  • EULA

Contributors


Syed A. Abutalib, MD
Assistant Director, Hematology & Bone Marrow
Transplantation Program
Director, Hematopoietic Progenitor Cell Collection Facility
Midwestern Regional Medical Center
Cancer Treatment Centers of America
Zion, IL, USA

Syed Abbas Ali, MD
Sydney Kimmel Comprehensive Cancer Center
Division of Hematologic Malignancies
Johns Hopkins University
Baltimore, MD, USA

Emanuele Angelucci, MD
Unità Operativa Ematologia.
IRCCS Azienda Ospedaliera Universitaria San Martino -
IST - Istituto Nazionale per la Ricerca sul Cancro
Genova, Italy

Harold Atkins, MD, FRCPC
Physician, Blood and Marrow Transplant Program
The Ottawa Hospital;
Scientist, Cancer Therapeutics Program
The Ottawa Hospital Research Institute
and
Associate Professor, Division of Hematology
University of Ottawa, Ottawa, Ontario, Canada

Asad Bashey, MD, PhD
The Blood and Marrow Transplant Group of Georgia at
Northside Hospital
Atlanta, GA, USA

Ludovic Belle, PhD
Medical College of Wisconsin
Milwaukee, WI, USA

Koen van Besien, MD
Division of Hematology and Oncology
Department of Medicine
Weill Cornell Medical College
New York, NY, USA

Melinda Biernacki, MD
Fred Hutchinson Cancer Research Center and
the University of Washington
Seattle, WA, USA

Jaap Jan Boelens, MD, PhD
University Medical Center Utrecht
Pediatric Blood and Marrow Transplantation Program
and
Laboratory Translational Immunology
University Medical Center Utrecht
Utrecht, The Netherlands

Catherine M. Bollard, MBChB, MD, FRACP, FRCPA
Children's National Medical Center
and
The George Washington University
Washington, DC, USA

Adam Bryant, MD
Bone Marrow Transplant Fellow
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Sonali Chaudhury, MD
Associate Professor of Pediatrics
Division of Pediatric Hematology/Oncology/Stem Cell
Transplantation
Ann & Robert H. Lurie Children's Hospital of Chicago
Northwestern University Feinberg School of Medicine
Chicago, IL, USA

Christina Cho, MD
Adult Bone Marrow Transplantation Service
Memorial Sloan Kettering Cancer Center
and
Weill Cornell Medical College
New York, NY, USA

Stefan O. Ciurea, MD
Department of Stem Cell Transplant and Cellular Therapy
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

Luciano J. Costa, MD, PhD
Division of Hematology and Oncology
Department of Medicine
University of Alabama at Birmingham, Birmingham, AL, USA

Daniel R. Couriel, MD, MS
Division of Hematology and Hematologic Malignancies
Huntsman Cancer Institute
University of Utah
Salt Lake City, UT, USA

Conrad R. Cruz, MD, PhD
Children's National Medical Center
and
The George Washington University
Washington, DC, USA

Anita D'Souza, MD
Medical College of Wisconsin
Milwaukee, WI, USA

H. Joachim Deeg, MD
Fred Hutchinson Cancer Research Center and
the University of Washington
Seattle, WA, USA

Binod Dhakal, MD, MS
Medical College of Wisconsin
Milwaukee, WI, USA

Andrew C. Dietz, MD, MS
Pediatric Hematology, Oncology, & Blood and Marrow
Transplantation
Children's Hospital Los Angeles
University of Southern California
Los Angeles, CA, USA

Eva Domingo-Domenech, MD
Clinical Hematology Department
Institut Català d'Oncologia - Hospital Duran i Reynals
Barcelona, Spain

William R. Drobyski, MD
Medical College of Wisconsin
Milwaukee, WI, USA

Daniel Egan, MD
Fred Hutchison Cancer Research Center
Seattle, WA, USA

Mahmoud Elsawy, MD, MSc
Clinical Research Division, Fred Hutchinson
Cancer Research Center
University of Washington School of Medicine, Seattle, WA, USA
and
Department of Medical Oncology
National Cancer Institute
Cairo University, Egypt

Narendranath Epperla, MD
Division of Hematology and Oncology
Medical College of Wisconsin
Milwaukee, WI, USA

Timothy S. Fenske, MD
Associate Professor of Medicine
Division of Hematology and Oncology
Medical College of Wisconsin
Milwaukee, WI, USA

Adele K. Fielding, MBBS, PhD, FRCP, FRCPath
UCL Cancer Institute
London, UK

Flore Sicre de Fontbrune, MD
Hematology Transplant Unit
Saint-Louis Hospital, APHP
and
National French Reference Center for Bone Marrow Failure
Paris, France

Stephen J. Forman, MD
City of Hope National Medical Center
Duarte, CA, USA

Daniel Fowler, MD
Experimental Transplantation and Immunology Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD, USA

Shuang Fu, MD
Blood & Marrow Transplant Program
Cleveland Clinic
Cleveland, OH, USA

Henry C. Fung, MD
Fox Chase Cancer Center
Temple Health
Philadelphia, PA, USA

Timothy Gilligan, MD, MS
Associate Professor in Medicine
Vice-Chair for Education
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH, USA

Corrado Girmenia, MD
Dipartimento di Ematologia, Oncologia, Anatomia
Patologica e Medicina Rigenerativa
Azienda Policlinico Umberto I
Sapienza University of Rome
Rome, Italy

John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Centre for Haemato-Oncology
Barts Cancer Institute
Queen Mary University of London
London, UK

David C. Halverson, MD
Experimental Transplantation and Immunology Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD, USA

Mehdi Hamadani, MD
Division of Hematology and Oncology
Medical College of Wisconsin
Milwaukee, WI, USA

Parameswaran Hari, MD, MRCP, MS
Armand Quick - William Stapp Professor of Hematology;
Interim Division Chief, Division of Hematology
and Oncology
and
Director, Adult Blood and Marrow Transplant Program
Medical College of Wisconsin
Milwaukee, WI, USA

Hamza Hashmi, MD
Department of Internal Medicine
Michigan State University
Grand Rapids, MI, USA

Dennis D. Hickstein, MD
Experimental Transplantation and Immunology
Branch,
National Cancer Institute
National Institutes of Health
Bethesda, MD, USA

Vincent T. Ho, MD
Dana Farber Cancer Institute
Boston, MA, USA

Amara S. Hussain, MD
Medical College of Wisconsin
Milwaukee, WI, USA

Racquel D. Innis-Shelton, MD
Division of Hematology and Oncology
Department of Medicine
University of Alabama at Birmingham
Birmingham, AL, USA

Madan Jagasia, MD, MBBS, MS
Hematology and Stem Cell Transplantation Section
Division of Hematology/Oncology
Department of Medicine,
Vanderbilt University Medical Center and Veterans Affairs
Medical Center;
Vanderbilt University School of Medicine
Nashville, TN, USA

Yogesh Jethava, MD, FACP, MRCP, FRCPath
Divison of Hematology and Oncology
University of Arkansas for Medical Sciences
Little Rock, AR, USA

Nisha S. Joseph, MD
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA, USA

Jennifer A. Kanakry, MD
Experimental Transplantation and Immunology Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD, USA

Natasha Kekre, MD, MPH, FRCPC
Blood and Marrow Transplant Program
The Ottawa Hospital and Ottawa Hospital Research Institute
Ottawa, Canada

Michael D. Keller, MD
Children's National Medical Center
and
The George Washington University
Washington, DC, USA

Vanessa E. Kennedy, MD
Vanderbilt University School of Medicine
Vanderbilt University Medical Center
Nashville, TN, USA

Piyanuch Kongtim, MD
Department of Stem Cell Transplant and Cellular Therapy
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

Amrita Krishnan, MD
City of Hope National Medical Center
Duarte, CA, USA

Nicolaus Kröger, MD
Department of Stem Cell Transplantation
University Medical Center Hamburg-Eppendorf
Hamburg, Germany

Patricia Kropf, MD
Fox Chase Cancer Center
Temple Health
Philadelphia, PA, USA

Hillard M. Lazarus, MD, FACP
Department of Medicine
University Hospitals Seidman Cancer Center
Case Western Reserve University
Cleveland, OH, USA

Sagar Lonial, MD
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA, USA

Navneet S. Majhail, MD, MS
Professor, Cleveland Clinic Lerner College of Medicine
and
Director, Blood & Marrow Transplant Program
Cleveland Clinic,
Cleveland, OH,...

Dateiformat: ePUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat ePUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

84,99 €
inkl. 7% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe-DRM
siehe Systemvoraussetzungen
E-Book bestellen